Current Pharmaceutical Design

William A. Banks  
VAPSHCS/GRECC S-182
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108
USA

Back

Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine

Author(s): Gilles Mees, Mike Sathekge, Alex Maes and Christophe Van de Wiele

Affiliation: University Hospital Ghent, Department of Nuclear Medicine, De Pintelaan 185, 9000-B Ghent, Belgium.

Keywords: Hypoxia, PET, SPECT, nitroimidazole.

Abstract:

Hypoxia is a characteristic feature of many solid tumors which has been described in a wide range of tumor types. Its presence impairs the effectiveness of common anti-cancer therapies and accordingly, tumor hypoxia has been associated with an aggressive tumor phenotype, poor response to radio- and chemotherapy, and worse prognosis. In order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments, in vivo measurement of tumor hypoxia is required. Given the difficulties associated with invasive methods, a non-invasive method is of major clinical interest. Although several candidate molecules have been labeled with PET and SPECT labels, none of them is used in daily clinical routine due to a number of difficulties that complicate their use. This review aims to give an overview of the most important hypoxia tracers, their prognostic significance and how these tracers can play a role in tomorrows personalized medicine.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 20
ISSUE: 14
Page: [2308 - 2318]
Pages: 11
DOI: 10.2174/13816128113196660662